Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 20 of the 33 sources its claims cite were checked for support.
Abstract
BACKGROUND: Prostate cancer (PCa) is a leading malignancy among men globally, with rising incidence rates emphasizing the critical need for better detection and therapeutic approaches. The roles of HSP90AB1 and PARP1 in prostate cancer cells suggest potential targets for enhancing treatment efficacy. METHODS: This study investigated the overexpression of HSP90AB1 and PARP1 in prostate cancer cells and the impact of HSP90AB1 knockdown on the sensitivity of these cells to the PARP inhibitor olaparib. We also explored the combined effect of olaparib and celastrol, an HSP90 inhibitor, on the clonogenic survival, migration, proliferation, and overall viability of prostate cancer cells, alongside the modulation of the PI3K/AKT pathway. An in vivo PC3 xenograft mouse model was used to assess the antitumor effects of the combined treatment. RESULTS: Our findings revealed significant overexpression of HSP90AB1 and PARP1 in prostate cancer cells. Knockdown of HSP90AB1 increased cell sensitivity to olaparib. The combination of olaparib and celastrol significantly reduced prostate cancer cell survival, migration, proliferation, and enhanced cumulative DNA damage. Celastrol also downregulated the PI3K/AKT pathway, increasing cell susceptibility to olaparib. In vivo experiments demonstrated that celastrol and olaparib together exerted strong antitumor effects. CONCLUSIONS: The study indicates that targeting both HSP90AB1 and PARP1 presents a promising therapeutic strategy for prostate cancer. The synergistic combination of celastrol and olaparib enhances the efficacy of treatment against prostate cancer, offering a potent approach to combat this disease.
Overview
CoChat Summary
TL;DR
Celastrol, an HSP90 inhibitor, combined with olaparib reduced prostate cancer cell clonogenicity, migration, proliferation, and viability while increasing DNA damage and downregulating PI3K/AKT. In PC3 xenografts, the combination reduced tumor weight and volume and Ki-67, suggesting a potential therapeutic strategy for prostate cancer.
Key findings
- HSP90AB1 and PARP1 were overexpressed in prostate cancer cell lines versus normal RWPE-1 cells and in TCGA PRAD tumor samples; high expression of either was associated with diminished overall survival in PCa patients.
- HSP90AB1 knockdown significantly enhanced sensitivity of 22RV1, PC3, and DU145 cells to olaparib at 20, 40, 60, and 80 µM.
- Celastrol (1 µM) plus olaparib (50 µM) more effectively reduced clonogenic survival, migration, proliferation, and viability than monotherapy, and increased γH2AX foci and comet tail moment, with downregulation of phosphorylated PI3K and AKT.
- In PC3 xenografts, celastrol (2 mg/kg) plus olaparib (30 mg/kg) given intraperitoneally thrice weekly for 3 weeks significantly reduced tumor weight (P < 0.001), tumor volume (P < 0.01), and Ki-67 expression (P < 0.01); major organ weights did not show appreciable changes.
Methods
- In vitro studies used RWPE-1, 22RV1, PC3, and DU145 cells; TCGA, R2, and GEPIA databases; HSP90AB1 shRNA knockdown; and assays including western blot, CCK-8, colony formation, wound scratch, EdU, immunofluorescence, immunohistochemistry, and alkaline comet assay.
- In vivo studies used male BALB/c nude mice, 5–6 weeks old, with subcutaneous PC3 xenografts; mice were randomized into groups of 6 and treated with DMSO, celastrol, olaparib, or combination, with tumor volume calculated as (length × width²)/2.
- Statistical analysis used mean ± SD from at least three experiments, Student’s two-tailed t-test, one-way ANOVA, GraphPad Prism 8.0, and significance at P < 0.05.
Limitations
- Stated in the paper: 22RV1 cells were not used in subsequent phenotypic experiments because they had difficulty forming a monolayer, which could affect experimental outcomes.
- Evident from the text: the paper does not include a formal limitations section; in vivo efficacy was tested only in a PC3 xenograft model with 6 mice per group, without survival endpoints or clinical validation.
- Evident from the text: toxicity assessment relied on body weight and major organ weights, without detailed histopathological or systemic toxicity analyses.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
13 Valid · 0 Not valid · 6 Not checked · 50 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In cancer cells, the PI3K/AKT pathway may be activated as a survival mechanism in response to the DNA damage caused by olaparib.”
§ Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer > Discussion
What the sources say
- Partly supportedcites [40] Wang D, Wang M, Jiang N, Zhang Y, Bian X, Wang X, Roberts TM, Zhao JJ, Liu P, Cheng H. Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer[J]. Oncotarget. 2016;7(11):13153. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) describes PI3K signaling as involved in cell survival, and the Results section on combined treatment reports that olaparib alone moderately induced DNA damage. But the paper does not say that olaparib-induced DNA damage activates PI3K/AKT as a survival response; the Results instead report reduced phosphorylated AKT with combined olaparib and BKM120 treatment. (LLM, conf=0.84)
- Could not verifycites [41] Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O’cearbhaill RE, Coleman RL, Kochupurakkal B. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial[J]. Lancet Oncol. 2019;20(4):570–80. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says PI3K inhibition increases DNA damage and sensitizes cancer cells to PARP inhibitors. Neither it nor the retrieved passages on the olaparib–alpelisib combination say that olaparib-induced DNA damage activates PI3K/AKT as a survival mechanism. Searches for that proposed activation and for AKT activation after PARP inhibition found no supporting passage in our copy. (LLM, conf=0.72)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Specifically focusing on prostate adenocarcinoma (PRAD), Fig. 1b revealed that HSP90AB1 transcripts are significantly elevated in primary tumor tissues compared to normal samples.”
- Also stated in: § The expression of HSP90AB1 and PARP1 are significantly higher in PCa and HSP90AB1 knockdown enhanced the sensitivity of PCa cell lines to olaparib · hedged
“The data indicated higher expression levels of these genes in tumor samples compared to normal tissues.”
§ Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer > Results > The expression of HSP90AB1 and PARP1 are significantly higher in PCa and HSP90AB1 knockdown enhanced the sensitivity of PCa cell lines to olaparib
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § The expression of HSP90AB1 and PARP1 are significantly higher in PCa and HSP90AB1 knockdown enhanced the sensitivity of PCa cell lines to olaparib · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Colony formation assays indicated that the co-administration of celastrol and olaparib significantly reduced the clonogenic capacity of PCa cells more effectively than either agent alone (Fig. 2a).”
- Also stated in: § Results · plain
“The combination of olaparib and celastrol significantly reduced prostate cancer cell survival, migration, proliferation, and enhanced cumulative DNA damage.”
§ Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer > Results > The combination of olaparib and celastrol was observed to more effectively attenuate clonogenicity, migration, proliferation, and overall viability in PCa cells
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our findings revealed significant overexpression of HSP90AB1 and PARP1 in prostate cancer cells.”
- Also stated in: § Background · plain
“In this study, we discovered that both HSP90AB1 and PARP1 are significantly overexpressed in PCa cell lines”
- Also stated in: § The expression of HSP90AB1 and PARP1 are significantly higher in PCa and HSP90AB1 knockdown enhanced the sensitivity of PCa cell lines to olaparib · plain
“protein levels of HSP90AB1 and PARP1 were found to be higher in the PCa cell lines relative to the normal control (Fig. 1g).”
§ Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer > Abstract > Results
plainstates an associationn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Background · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our findings revealed significant overexpression of HSP90AB1 and PARP1 in prostate cancer cells.”
- Also stated in: § Background · plain
“In this study, we discovered that both HSP90AB1 and PARP1 are significantly overexpressed in PCa cell lines”
- Also stated in: § The expression of HSP90AB1 and PARP1 are significantly higher in PCa and HSP90AB1 knockdown enhanced the sensitivity of PCa cell lines to olaparib · plain
“protein levels of HSP90AB1 and PARP1 were found to be higher in the PCa cell lines relative to the normal control (Fig. 1g).”
§ Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer > Abstract > Results
plainstates an associationn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Background · plain
39 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 16
- It may state two separate claims as one. 10
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer > Results > The expression of HSP90AB1 and PARP1 are significantly higher in PCa and HSP90AB1 knockdown enhanced the sensitivity of PCa cell lines to olaparib
“we observed a significant positive correlation between the expression of PARP1 and HSP90AB1 proteins (Fig. 1h).”
§ Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer > Results > The expression of HSP90AB1 and PARP1 are significantly higher in PCa and HSP90AB1 knockdown enhanced the sensitivity of PCa cell lines to olaparib
“(h) Correlation of HSP90AB1 and PARP1 gene expression in PCa samples.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer > Results > The combination of olaparib and celastrol was observed to more effectively attenuate clonogenicity, migration, proliferation, and overall viability in PCa cells
“The results demonstrated that the combined treatment significantly inhibited the proliferation and viability of PC3 and DU145 cells compared to the monotherapy groups (Fig. 2d and f).”
§ Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer > Results > The combination of olaparib and celastrol was observed to more effectively attenuate clonogenicity, migration, proliferation, and overall viability in PCa cells
“(d-e) Evaluation of proliferation and viability in PC3 and DU145 cell lines subjected to treatments with DMSO, celastrol (1 µM), olaparib (50 µM), and their combination through EdU and CCK-8 assays.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer > Results > Olaparib and celastrol augment cumulative DNA damage in PCa cells
“However, the concomitant administration of celastrol and olaparib markedly intensified DNA damage in PC3 and DU145 cells (Fig. 3c).”
§ Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer > Results > Olaparib and celastrol augment cumulative DNA damage in PCa cells
“(c) Comet assay of PC3 cells treated with celastrol (1 µM) and olaparib (50 µM), either agent alone, or DMSO, for 48 h.”
Citations
Cites
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810696 · Cited by 2,906 · cited 2×
“Prostate cancer (PCa) is one of the most prevalent malignancies affecting men globally, marked by its heterogeneous nature and variable clinical outcomes [1, 2].”
BackgroundMaintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870 · cited 1×
“Olaparib, has shown substantial efficacy in various cancers, including ovarian, breast, and PCa [26–28].”
BackgroundThe mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517 · cited 2×
“Prostate cancer (PCa) is one of the most prevalent malignancies affecting men globally, marked by its heterogeneous nature and variable clinical outcomes [1, 2].”
BackgroundHSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502 · cited 1×
“HSP90AB1 is commonly overexpressed in a variety of cancers, with this upregulation typically linked to poor prognostic outcomes and increased resistance to standard chemotherapy and radiotherapy treatments [12, 42, 43].”
BackgroundOlaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323 · cited 3×
“In PCa, olaparib has gained attention for its effectiveness in patients with mutations in DNA repair genes, offering a targeted treatment approach [28, 30].”
BackgroundHSP90 at the hub of protein homeostasis: emerging mechanistic insights
Taipale, M., Jarosz, D. F., & Lindquist, S. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2918 · Cited by 1,818 · cited 2×
“By stabilizing a wide range of oncoproteins, such as kinases, hormone receptors, and transcription factors, HSP90AB1 inadvertently promotes the malignant phenotype [19, 20].”
BackgroundAdjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer
Tutt, A. N. J., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., Gelber, R. D., de Azambuja, E., Fielding, A., Balmaña, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105215 · Cited by 1,729
Overdiagnosis and Overtreatment of Prostate Cancer
Loeb, S., Bjurlin, M. A., Nicholson, J., Tammela, T. L., Penson, D. F., Carter, H. B., Carroll, P., & Etzioni, R. (2014) · European Urology · doi:10.1016/j.eururo.2013.12.062 · Cited by 964 · cited 1×
“Early detection through screening, such as PSA (Prostate-Specific Antigen) testing, has been pivotal in identifying potential cases, yet it raises concerns regarding over-diagnosis and overtreatment [1, 7].”
BackgroundAdverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
Nguyen, P. L., Alibhai, S. M. H., Basaria, S., D’Amico, A. V., Kantoff, P. W., Keating, N. L., Penson, D. F., Rosario, D. J., Tombal, B., & Smith, M. R. (2015) · European Urology · doi:10.1016/j.eururo.2014.07.010 · Cited by 831 · cited 1×
“However, its effectiveness diminishes over time with the development of castration-resistant prostate cancer (CRPC), and prolonged use leads to significant side effects like osteoporosis and cardiovascular issues [9].”
Background
Cited by
Li, S., Jing, S., Zhou, J., Li, H., Yin, P., zhang, Q., Gong, M.-S., Zhao, Y., Lu, G.-G., Jin, G.-H., et al. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120471 · Cited by 6
Nikitha, S., Manjula, D., & Nasrine, A. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107076 · Cited by 2
Deng, Y., Wang, J. S., Liu, X., Chen, Y., Wang, M., Wang, X., Li, H., Gu, B., Zhang, M., Wang, R., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093849 · Cited by 2
“The results of several studies have demonstrated its anticancer properties, including the promotion of apoptosis and the inhibition of cell invasion, angiogenesis, and proliferation [14,15].”
Targeting ER stress in adrenocortical carcinoma: Celastrol as a novel therapeutic candidate
Schiavon, A., Evaristo, C., Saba, L., Petiti, J., Pignochino, Y., Puglisi, S., Perotti, P., Messina, E., Giachino, C., Terzolo, M., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119156
Metadata
- Authors
- Huang, M., Chen, L., Ma, X., & Xu, H.
- Affiliations
- Guiyang University (CN)
- Guizhou Institute of Technology (CN)
- Guizhou University (CN)
- Corresponding author
- Xu, Houqiang
- Venue
- Cancer Cell International
- Published
- 2024-10-26
- Volume
- 24
- Issue
- 1
- Pages
- 352-352
- ISSN
- 1475-2867 (ISSN-L)
- PMC
- PMC11514812
- OpenAlex
- W4403784131
- Cited by
- 9
- References
- 42
- Citations by year
- 2026: 4 · 2025: 5
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Cancer Cell International (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Zunyi City Science and Technology Plan Project (Zun City Science and Technology Cooperation HZ No. (2023) 248)
- National Natural Science Foundation of China (31860242)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- prostate cancer, celastrol, olaparib, HSP90AB1, PARP1, PARP inhibitors, Hsp90 inhibitors, combination therapy, cell invasion, cell migration, PI3K/Akt signaling, DNA damage, tumor xenografts, synergistic antitumor effect
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer. https://app.cochat.ai/papers/10.1186/s12935-024-03542-8
- The paper
- Huang, M., Chen, L., Ma, X., & Xu, H. (2024). Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer. Cancer Cell International. https://doi.org/10.1186/s12935-024-03542-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.